SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Stepping stones to success, progress or milestone pathway to achieve target, small step to overcome difficulty, development stages concept, confidence businessman stepping on stones across ocean.
Career Advice
Stop Optimizing Your Job, Start Optimizing Your Career
The difference between a job and a career is what you walk away with when it ends. Here’s how to evaluate if your role and environment are enabling capability building–and if your title is holding you back.
December 11, 2025
 · 
5 min read
 · 
Angela Justice
Thumb up close-up in surgical, medical gloves, gesture, recommendation for a successful operation. Pink background.
Rare diseases
FDA Greenlights First Gene Therapy for Rare Pediatric Disease
Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a non-profit sponsor to win FDA approval.
December 10, 2025
 · 
1 min read
 · 
Tristan Manalac
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
Vaccines
FDA Launches Probe Into Safety of Approved Anti-RSV Antibodies
The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains unclear what regulatory action, if any, will be taken.
December 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc
Approvals
First Commissioner’s Priority Review Approval Goes to Decades-Old Antibiotic
The Commissioner’s National Priority Voucher program was launched in June to shorten review times for companies that align with various national priorities, such as improving domestic drug production and supply.
December 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
Pfizer deals again in obesity space as Wave and Structure drop splashy weight loss results; what CDER Director Richard Pazdur’s sudden retirement means for biopharma; neuro diseases take center stage at CTAD; and more.
December 10, 2025
 · 
1 min read
 · 
Heather McKenzie
Hand with the ace of Spades playing card. Vintage color engraving stylized drawing. Vector illustration
Mergers & acquisitions
Pfizer Is Not a Done Dealmaker After Metsera Buy, With $6B More To Spend
With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, particularly in internal medicine and immunology and inflammation, Guggenheim reported.
December 10, 2025
 · 
1 min read
 · 
Annalee Armstrong
Hands holding red circle. Sensing energy between palms. Concept of human relation, togetherness, partnership, connection, contact or network. Design for banner, flyer, poster, cover or brochure.
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
 · 
7 min read
 · 
Dan Samorodnitsky
Vector illustration of businessmen on a roller coaster ride bar graph
Regulatory
Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this summer—the lowest they’d been since early 2021. But they now sit higher than they did at the start of the year.
December 10, 2025
 · 
3 min read
 · 
Annalee Armstrong
Two businessmen negotiating with big speech bubbles
Rare diseases
Saol To Pitch Ultrarare Disease Drug as “Poster Child” for RDEP Program
Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week after the FDA unveiled its Rare Disease Evidence Principles program. On Dec. 18, in a Type A meeting, the biotech will attempt to convince the agency that its drug fits perfectly into the framework.
December 9, 2025
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS